Point72 Hong Kong Ltd purchased a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 855 shares of the company’s stock, valued at approximately $35,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of PRCT. Credit Suisse AG lifted its holdings in shares of PROCEPT BioRobotics by 6.0% during the 3rd quarter. Credit Suisse AG now owns 7,594 shares of the company’s stock worth $314,000 after acquiring an additional 430 shares during the period. JPMorgan Chase & Co. boosted its holdings in PROCEPT BioRobotics by 18.2% during the first quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company’s stock valued at $188,000 after purchasing an additional 825 shares in the last quarter. UBS Group AG grew its stake in shares of PROCEPT BioRobotics by 127.9% in the 3rd quarter. UBS Group AG now owns 1,823 shares of the company’s stock valued at $75,000 after purchasing an additional 1,023 shares during the period. US Bancorp DE bought a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at approximately $37,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of PROCEPT BioRobotics by 2.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 51,391 shares of the company’s stock worth $1,799,000 after buying an additional 1,206 shares in the last quarter. Institutional investors own 66.40% of the company’s stock.
Insider Buying and Selling at PROCEPT BioRobotics
In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 20,000 shares of the company’s stock in a transaction on Monday, December 19th. The shares were sold at an average price of $43.23, for a total transaction of $864,600.00. Following the completion of the sale, the executive vice president now owns 7,126 shares in the company, valued at approximately $308,056.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 43,064 shares of company stock valued at $1,829,318. 40.80% of the stock is currently owned by insiders.
PROCEPT BioRobotics Trading Up 3.3 %
Analysts Set New Price Targets
Several brokerages have recently commented on PRCT. Truist Financial decreased their target price on PROCEPT BioRobotics from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, January 31st. Wells Fargo & Company decreased their price target on shares of PROCEPT BioRobotics from $52.00 to $43.00 and set an “overweight” rating on the stock in a research note on Thursday, January 12th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and an average price target of $44.38.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Stories
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating).
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
